Percentage of survival in vector- A. or IRIS- B. overexpressing T47D cells, as well as shcontrol- C. or shIRIS- D. expressing MDA468 cells following incubation with increasing concentration of anti-CD24 monoclonal antibody for the indicated times. E. FACS analysis of non-permeabilized MCF7 cells incubated with FITC-CD44 and PE-CD24 antibodies for only 20mins. F. Expression of IRIS mRNA in non-CD44-/CD24+ and TIC-CD44+/CD24- MCF7 cells, or non-CD44-/CD24+ and TIC-like-CD44-/CD24- T47D cells sorted as in (E). G. Real time QRT/PCR analysis for the expression of IRIS and the indicated basal-biomarkers, EMT-inducers, and stemness-enforcers mRNA in MCF7 TIC-CD44+/CD24- cells compared to non-CD44-/CD24+ cells, and T47D TIC-like-CD44-/CD24- cells compared to non-CD44-/CD24+ cells sorted as in (E). H-J. Western blot analysis for the expression of IRIS and the indicated basal-biomarkers, EMT-inducers, and stemness-enforcers non-CD44-/CD24+ and TIC-CD44+/CD24- MCF7 cells, or non-CD44-/CD24+ and TIC-like-CD44-/CD24- T47D cells sorted as in (E). K. Numbers and diameters of mammospheres developed by non-CD44-/CD24+ and TIC-CD44+/CD24- MCF7 cells, or non-CD44-/CD24+ and TIC-like-CD44-/CD24- T47D cells sorted as in (E). L. RT/PCR analysis of IRIS mRNA in parental, non-TIC and TIC MCF7 cells sorted as in (E) before and after IRIS silencing. Mammosphere formation by non-TIC M. parental unsorted N., TIC O. MCF7 cells before or after anti-CD24 blocking antibody + siLuc P. vehicle + siIRIS Q. or anti-CD24 blocking antibody + siIRIS R. treatment. S. Schematic presentation of our hypothesis of sensitizing TNBC/TIC cells to anti-CD24 blocking antibody through IRIS silencing/inhibition.